Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gill

Showing results (361-370 of 376) with videos related to

Pageof 38
Sort By:
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
Emerging Microbes & Infections|June 4, 2015
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in miceArmin Hekele, Sylvie Bertholet, Jacob Archer, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Frontiers in Cardiovascular Medicine|February 17, 2022
Prognostic Value of Coronary CT Angiography-Derived Fractional Flow Reserve in Non-obstructive Coronary Artery Disease: A Prospective Multicenter Observational StudyFan Zhou, Qian Chen, Xiao Luo, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Nature|January 5, 2000
Sequence and analysis of chromosome 2 of the plant Arabidopsis thalianaX Lin, S Kaul, S Rounsley, et al.
Intensive Care Medicine Experimental|March 19, 2021
National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis researchAsher A Mendelson, Casey Lansdell, Alison E Fox-Robichaud, et al.
Pageof 38

Showing results (361-370 of 376) with videos related to

Sort By:
Pageof 38
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
Emerging Microbes & Infections|June 4, 2015
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in miceArmin Hekele, Sylvie Bertholet, Jacob Archer, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Frontiers in Cardiovascular Medicine|February 17, 2022
Prognostic Value of Coronary CT Angiography-Derived Fractional Flow Reserve in Non-obstructive Coronary Artery Disease: A Prospective Multicenter Observational StudyFan Zhou, Qian Chen, Xiao Luo, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Nature|January 5, 2000
Sequence and analysis of chromosome 2 of the plant Arabidopsis thalianaX Lin, S Kaul, S Rounsley, et al.
Intensive Care Medicine Experimental|March 19, 2021
National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis researchAsher A Mendelson, Casey Lansdell, Alison E Fox-Robichaud, et al.
Pageof 38